Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website; (3) the federal government Internet portal; or (4) a web search conducted using a commercial search engine such as
Accession Number ADA575574
Title Inhibition of Orthopaedic Implant Infections by Immunomodulatory Effects of Host Defense Peptides.
Publication Date Oct 2012
Media Count 7p
Personal Author E. Greenfield
Abstract Host defense peptides represent a promising new approach to inhibit infection. The anti-infective actions of these peptides are primarily due to their immunomodulatory effects. Since they regulate multiple aspects of the mammalian immune system, host defense peptides are also less likely to induce bacterial resistance than are traditional antibiotics. The local delivery of anti-bacterial agents allows for both high local concentrations to increase efficacy and low systemic levels to reduce toxicity. A promising strategy for the local delivery of anti-bacterial agents is to bind them directly to the surfaces of orthopaedic implants. The progress in the second year of this project has demonstrated: 1. Development of a quantitative and reproducible murine model of orthopaedic implant infection. 2. Preliminary results indicate that the soluble host defense peptide reduces orthopaedic implant infection in the murine model. 3. Preliminary results indicate that the soluble host defense peptides increases osseointegration in mice that were not inoculated with bacteria. The host defense peptides have the potential to substantially reduce infections of fractures sustained on the battlefield and in civilian settings. If the synthetic peptide reduces infections in the studies proposed in this application, more extensive pre-clinical testing would precisely determine its potential benefits and risks and determine whether the peptide is a high priority for human trials.
Keywords Acinetobacter baumannii
Clinical medicine
Defense systems
Host defense peptides
Infectious diseases
Murine model
Orthopaedic infections
Staphylococcus aureus

Source Agency Non Paid ADAS
NTIS Subject Category 57E - Clinical Medicine
Corporate Author Case Western Reserve Univ., Cleveland, OH.
Document Type Technical report
Title Note Annual rept. 15 Sep 2011-14 Sep 2012.
NTIS Issue Number 1319
Contract Number W81XWH-10-1-0872

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader